NanoViricides (NNVC) vs ProMIS Neurosciences (PMN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
NanoViricides (NNVC) has outperformed ProMIS Neurosciences (PMN) over the past year, losing 10.2% versus a loss of 69.9%. Over five years, NNVC leads with a -76.5% price change compared with -98.2% for PMN. NanoViricides is the larger company by market cap ($29.1 million vs $28.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NNVC | PMN |
|---|---|---|
| Share price | $1.14 | $3.16 |
| Market cap | $29.13M | $28.43M |
| 1-day change | -2.56% | -1.56% |
| YTD return | +0.88% | -53.73% |
| 1-year return | -10.24% | -69.90% |
| 5-year return | -76.54% | -98.24% |
| EPS (TTM) | $-0.53 | $-6.50 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | — |
| Net income (latest FY) | $-8.22M | $-39.72M |
| 52-week high | $1.93 | $27.40 |
| 52-week low | $0.85 | $2.78 |
| Distance from 52-week high | -40.93% | -88.47% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +426.32% | +1248.42% |
| Average volume | 356.86K | 164.88K |
| Shares outstanding | 25.55M | 9.00M |
| Employees | 7 | 10 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NNVC has outperformed PMN by 59.7 percentage points over the past year.
About NanoViricides
NNVC stock →NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection; The latter, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About ProMIS Neurosciences
PMN stock →ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
NNVC vs PMN FAQ
Which is bigger, NanoViricides or ProMIS Neurosciences?
NanoViricides (NNVC) is larger, with a market capitalization of $29.13M compared with $28.43M for ProMIS Neurosciences (PMN).
Which stock has performed better over the past year, NNVC or PMN?
NNVC returned -10.24% over the past 12 months, compared with -69.90% for PMN (price return, excluding dividends). Past performance does not predict future results.
Are NanoViricides and ProMIS Neurosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.